Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
2.17% $0.368
America/New_York / 22 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 9.88 mill |
EPS: | -0.550 |
P/E: | -0.670 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 26.87 mill |
Avg Daily Volume: | 0.358 mill |
RATING 2024-04-22 |
---|
C |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.670 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.11x |
Company: PE -0.670 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.253 (-168.79%) $-0.621 |
Date: 2024-04-22 |
Expected Trading Range (DAY) |
---|
$ 0.334 - 0.402 ( +/- 9.24%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-19 | Frost Phillip Md Et Al | Sell | 129 802 | Common Stock |
2023-10-18 | Blank Andrew Scott | Buy | 12 434 | Stock Option (right to buy) |
2023-10-18 | Krasno Richard M | Buy | 12 434 | Stock Option (right to buy) |
2023-10-18 | Moyes Jay M | Buy | 12 434 | Stock Option (right to buy) |
2023-10-18 | Allen Jim L. | Buy | 12 434 | Stock Option (right to buy) |
INSIDER POWER |
---|
69.02 |
Last 98 transactions |
Buy: 2 428 796 | Sell: 415 660 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.368 (2.17% ) |
Volume | 0.0514 mill |
Avg. Vol. | 0.358 mill |
% of Avg. Vol | 14.36 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $0.400 | N/A | Active |
---|
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.